LOKELMA

Peak

sodium zirconium cyclosilicate

NDAORALFOR SUSPENSION
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
18

Mechanism of Action

(sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. In vitro , LOKELMA has a high affinity for potassium ions, even in the presence of other cations such as calcium and magnesium. LOKELMA increases fecal…

Indications (1)

Clinical Trials (5)

NCT06635499N/ACompleted

VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain

Started Nov 2024
232 enrolled
Hyperkalaemia
NCT06365684Phase 4Recruiting

Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4

Started Apr 2024
16 enrolled
HyperkalemiaDiet ModificationChronic Kidney Disease+1 more
NCT06185660N/ACompleted

A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece

Started Feb 2024
125 enrolled
Hyperkalaemia
NCT05535920Phase 4Completed

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Started Apr 2022
88 enrolled
Hyperkalemia
NCT05347693Phase 4Completed

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

Started Mar 2022
186 enrolled
HyperkalaemiaChronic Kidney Disease

Loss of Exclusivity

LOE Date
Oct 14, 2035
116 months away
Patent Expiry
Oct 14, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
8808750
Feb 10, 2032
U-2312
10398730
Feb 10, 2032
U-2312
9844567
Feb 10, 2032
U-2312
10413569
Feb 10, 2032
Substance
10335432
Feb 10, 2032
U-2312